Global Markets for Orphan Drugs - Focus on Non-Biologics

Report Code: PHM151A

Publish Date: Jun 2013

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

Report Includes

  • An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends; this report focuses on non-biologics.
  • Analyses of global market trends, with data from 2010 to 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • Detailed discussion of successful orphan products.
  • Detailed analysis of blockbuster orphan drugs.
  • The rising influence of pharmacogenomics in the orphan drug market.
  • A discussion of specific rare diseases for which orphan drugs exist.
  • Analyses of the most promising therapeutic areas in the industry and leading orphan drugs in these areas.
  • An outline of legislation and regulation, including public and private agencies involved in support and development.
  • Technology trends analysis within the orphan drug market.
  • Comprehensive company profiles of major players in the industry.

INTRODUCTION

STUDY OBJECTIVES

The orphan drug market is one of the fastest-growing segments in the pharmaceutical and biotechnology industry.  BCC’s goal in conducting this study is to provide an overview of the current and future global market for orphan drugs.  The key objective is to present a comprehensive analysis of current orphan drugs and those under development as important therapies and treatments for rare diseases.

This report explores present and future strategies and regulations within the orphan drug market, advances in the market, the setbacks, the current situation and the needs of the market.  The market for each drug listed by its generic name/active ingredient and approved indication(s) is also analyzed in this report.

A detailed analysis of the structure of the orphan drug industry has been conducted.  Revenues are broken down by region drug type (i.e., biological and nonbiological), active ingredient and area of medical application.  Sales figures are estimated for the five-year period from 2012 through 2017.

Applications for orphan drugs are also discussed in the report, with an emphasis on the usage of the drugs in various disease segments.  The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of orphan drugs has resulted in therapeutic treatments for a number of rare diseases.  Most of the big pharmaceutical companies have now begun to explore the advantages of orphan drugs as a major source of profit and a steady market.

R&D spending, competition and new technologies are increasing.  Advances, new product launches and assistance from regulatory bodies are positively impacting the growth of the market for orphan drugs in the near term.  This study examines these factors.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This study focuses on the manufacturers and users of orphan drugs and its market growth.  Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study includes orphan drugs in pharmaceutical markets worldwide.  BCC analyzes each market and its applications, regulatory environment, technology, market projections and market shares.  Technological issues include the latest trends and developments.  The emerging market for orphan drugs includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study.  BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources.  Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study.  Included were manufacturers and end users of orphan drugs within the therapeutic categories examined and various disease sector industries.  Data were gathered from various industry sources.  BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts.  Exhaustive investigations of databases by key terminology were completed.  In addition, data were compiled from current financial, trade and government sources.

BCC Research offers an online information retrieval service.  Its home page, located at www.bccresearch.com, enables readers to:

  • Examine BCC’s complete catalog of Market Research Reports and place direct orders.
  • Subscribe to any of BCC’s many industry newsletters.
  • Read announcements of upcoming reports and newly launched newsletters.
  • Register for BCC’s well-known conferences.
  • Request additional information about any BCC product.
  • Take advantage of special offers.

To reach this important new information resource, go to www.bccresearch.com.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice; nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Markets for Orphan Drugs - Focus on Non-Biologics148Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: EXECUTIVE SUMMARY3Free
Chapter- 3: OVERVIEW23Free
Chapter- 4: NEW PRODUCT DEVELOPMENT AND REGULATION OF ORPHAN DRUGS21Free
Chapter- 5: GLOBAL MARKET FOR ORPHAN DRUGS32Free
Chapter- 6: MARKET ANALYSIS OF NONBIOLOGICAL ORPHAN DRUGS34Free
Chapter- 7: PATENT ANALYSIS7Free
Chapter- 8: CURRENT SITUATION4Free
Chapter- 9: C. CRAMER & CO. GMBH21Free

Related Reports

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - Jan 2013 | Publisher - Jackson Highsmith | Code - BIO079B

The market for biologics was valued at $150 billion in 2011 and should reach $163 billion in 2012. Total market value is expected to reach $252 billion in 2017 after increasing at a five-year compound annual growth rate of 9%. 

Global Markets for Diabetes Therapeutics and Diagnostics

Published - Jan 2013 | Publisher - Paul Evers | Code - HLC029D

The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012.  Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.

Biosimilars: Global Markets

Published - May 2012 | Publisher - Syamala Ariyanchira | Code - BIO090A

The global market for biosimilars reached $1.7 billion in 2010 and $2.5 billion in 2011. The market is expected to reach $3.6 billion by 2016, a compound annual growth rate (CAGR) of 7.7%.

Antibody Drugs: Technologies and Global Markets

Published - Feb 2012 | Publisher - Esther Bosklopper | Code - BIO016H

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 39

  • Summary Table: GLOBAL SALES OF ORPHAN DRUGS BY TYPE, THROUGH 2017
  • Table 1: HISTORY OF ORPHAN DRUG LEGISLATION
  • Table 2: U.S. ORPHAN DRUG ACT, AMENDMENTS AND OTHER LEGISLATION
  • Table 3: NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2012
  • Table 4: COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN
  • Table 5: BIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION
  • Table 6: NONBIOLOGICAL ORPHAN DRUGS BY TRADE NAME AND INDICATION
  • Table 7: EXAMPLES OF ORPHAN DRUGS, INDICATIONS AND PREVALENCE OF DISEASES
  • Table 8: COMPANIES WITH MORE THAN FIVE ORPHAN DRUG APPROVALS,* 1983–2012
  • Table 9: ORPHAN DRUG MARKETING APPROVALS, 2008 THROUGH FEB. 2013
  • Table 10: ORPHAN DRUG SAFETY ALERTS AND RECALLS, 2008-2013
Sample Report

Recent Reports

Global Markets for Infectious Disease Treatments

Published - Jul 2025 | Publisher - BCC Publishing | Code - PHM061F

The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.

Disease-Modifying Therapies for Alzheimer’s Disease: Global Markets

Published - Jun 2025 | Publisher - BCC Publishing | Code - PHM283A

This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.

Global Markets for Allergy Diagnostics and Treatments

Published - Jun 2025 | Publisher - BCC Publishing | Code - PHM026D

The global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual rate growth (CAGR) of 7.3% from 2025 through 2030.

Over-the-Counter (OTC) Drugs, and Vitamins & Dietary Supplements: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - PHM050D

The global market for over-the- counter (OTC) drugs, vitamins and dietary supplements is expected to grow from $276.9 billion in 2025 and is projected to reach $371.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2025 to 2030.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

Published - May 2025 | Publisher - BCC Publishing | Code - PHM263B

This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Top Trending Reports

Sensors: Technologies and Global Markets

Published - Jun 2025 | Publisher - BCC Publishing | Code - IAS006Q

The global market for sensors was valued at $195.1 billion in 2024 and is estimated to increase from $212.5 billion in 2025 to reach $323.3 billion by 2030, at a compound annual growth rate (CAGR) of 8.7% from 2025 through 2030.

Global Cell Line and Membrane Market

Published - Jun 2025 | Publisher - BCC Publishing | Code - BIO178B

The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.

Water and Wastewater Treatment Technologies: Global Markets

Published - Jun 2025 | Publisher - BCC Publishing | Code - ENV008G

The global market for water and wastewater treatment technologies is expected to grow from $350.7 billion in 2025 and is projected to reach $591.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2025 to 2030.

Global Edge AI Market

Published - Jun 2025 | Publisher - BCC Publishing | Code - IFT310A

The global market for edge AI was valued at $8.7 billion in 2024 and is estimated to increase from $11.8 billion in 2025 to reach $56.8 billion by 2030, at a compound annual growth rate (CAGR) of 36.9% from 2025 through 2030.

Global Biochip Markets: Microarrays and Lab-on-a-Chip

Published - Jun 2025 | Publisher - BCC Publishing | Code - BIO049G

The global market for biochip was valued at $16.1 billion in 2024 and is estimated to reach $27.8 billion by 2029, at a compound annual growth rate (CAGR) of 11.6% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets for Orphan Drugs - Focus on Non-Biologics
Customize Report
AI: Your Say